mr garnier said the company had absorbed over Â£15bn of lost sales to generics but still managing to grow the businesschief executive jeanpierre garnier said it had been a difficult year2005 will also be an important year in terms of research and development pipeline progresshowever the firm discontinued development of an experimental treatment for obesity known as 771 after disappointing clinical trial results
